PE20051000A1 - 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metil propionico (cci-779)" - Google Patents
42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metil propionico (cci-779)"Info
- Publication number
- PE20051000A1 PE20051000A1 PE2004001059A PE2004001059A PE20051000A1 PE 20051000 A1 PE20051000 A1 PE 20051000A1 PE 2004001059 A PE2004001059 A PE 2004001059A PE 2004001059 A PE2004001059 A PE 2004001059A PE 20051000 A1 PE20051000 A1 PE 20051000A1
- Authority
- PE
- Peru
- Prior art keywords
- cci
- hydroximethyl
- hydroxy
- propionic acid
- methyl propionic
- Prior art date
Links
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 title abstract 3
- 229960000235 temsirolimus Drugs 0.000 title abstract 3
- 229960002930 sirolimus Drugs 0.000 title abstract 2
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Epoxy Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UN METODO DE TRATAMIENTO QUE CONSISTE EN PROPORCIONAR 42-ESTER DE RAPAMICINA CON ACIDO 3-HIDROXI-2-(HIDROXIMETIL)-2-METILPROPIONICO (CCI-779) DE ADMINISTRACION INTRAVENOSA EN UNA DOSIS DE 10-100 MG POR SEMANA O DE ADMINISTRACION ORAL EN UNA DOSIS DE 100-250 MG POR SEMANA. SE REFIERE TAMBIEN A UN PAQUETE FARMACEUTICO EL CUAL CONTIENE UN CICLO DE TRATAMIENTO QUE COMPRENDE UN ENVASE DE 1-4 UNIDADES DE CCI-779 EN UNA FORMA DE DOSIFICACION UNITARIA PARA EL TRATAMIENTO DEL LINFOMA DE CELULAS DEL MANTO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51732903P | 2003-11-04 | 2003-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20051000A1 true PE20051000A1 (es) | 2006-02-03 |
Family
ID=34590151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004001059A PE20051000A1 (es) | 2003-11-04 | 2004-11-02 | 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metil propionico (cci-779)" |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20050113403A1 (es) |
| EP (1) | EP1682131B9 (es) |
| JP (1) | JP4856548B2 (es) |
| KR (1) | KR101387988B1 (es) |
| CN (1) | CN1901906B (es) |
| AR (1) | AR046194A1 (es) |
| AT (1) | ATE373477T1 (es) |
| AU (1) | AU2004289213B2 (es) |
| BR (1) | BRPI0415714A (es) |
| CA (1) | CA2543665C (es) |
| CO (1) | CO5690605A2 (es) |
| CR (1) | CR8383A (es) |
| DE (1) | DE602004009098T2 (es) |
| DK (1) | DK1682131T3 (es) |
| EC (1) | ECSP066600A (es) |
| ES (1) | ES2291954T3 (es) |
| GT (1) | GT200400224A (es) |
| IL (2) | IL175128A0 (es) |
| MY (1) | MY136436A (es) |
| NO (1) | NO20062271L (es) |
| PA (1) | PA8616601A1 (es) |
| PE (1) | PE20051000A1 (es) |
| PL (1) | PL1682131T3 (es) |
| PT (1) | PT1682131E (es) |
| RU (1) | RU2358731C2 (es) |
| SA (1) | SA04250375B1 (es) |
| TW (1) | TW200517116A (es) |
| UA (1) | UA83697C2 (es) |
| WO (1) | WO2005046681A1 (es) |
| ZA (1) | ZA200603533B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
| US20080207644A1 (en) * | 2006-11-27 | 2008-08-28 | Sonis Stephen T | Therapeutic materials and methods |
| CN104004060B (zh) * | 2014-06-23 | 2016-04-13 | 重庆医科大学 | Cyclin D蛋白抑制剂多肽及其应用 |
| CN104017051B (zh) * | 2014-06-23 | 2016-08-17 | 深圳市华中生物药械有限公司 | 一种Cyclin D 蛋白抑制剂多肽及其应用 |
| CN104031122B (zh) * | 2014-06-23 | 2016-05-11 | 常州市肿瘤医院 | 有关Cyclin D蛋白抑制剂多肽及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5A (en) * | 1836-08-10 | Thomas Blanchard | Machine for mortising solid wooden shells of ships' tackle-blocks | |
| US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
| TWI256395B (en) | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
| DE60136200D1 (de) * | 2000-09-19 | 2008-11-27 | Wyeth Corp | Wasserlösliche rapamycin-ester |
| TWI286074B (en) * | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
| TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
| BR0210101A (pt) | 2001-06-01 | 2004-06-08 | Wyeth Corp | Combinações antineoplásticas |
| UA78706C2 (en) * | 2001-06-01 | 2007-04-25 | Wyeth Corp | Combination of rapamycin derivative and antitumor alkylating agent and method for treating soft tissue sarcoma and colonic cancer |
| ZA200603888B (en) * | 2001-06-01 | 2007-05-30 | Wyeth Corp | Antineoplastic combinations |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| AU2003210787B2 (en) | 2002-02-01 | 2009-04-23 | Medinol Ltd. | Phosphorus-containing compounds & uses thereof |
| CA2493878C (en) * | 2002-07-30 | 2013-07-23 | Wyeth | Parenteral formulations containing a rapamycin hydroxyester |
| RU2005136222A (ru) * | 2003-04-22 | 2006-03-20 | Уайт (Us) | Противоопухолевые комбинации |
| TW200524864A (en) | 2003-11-10 | 2005-08-01 | Wyeth Corp | Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands |
| AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
-
2004
- 2004-10-25 AR ARP040103876A patent/AR046194A1/es unknown
- 2004-10-28 UA UAA200606167A patent/UA83697C2/ru unknown
- 2004-10-28 CA CA002543665A patent/CA2543665C/en not_active Expired - Lifetime
- 2004-10-28 CN CN2004800397222A patent/CN1901906B/zh not_active Expired - Lifetime
- 2004-10-28 DE DE602004009098T patent/DE602004009098T2/de not_active Expired - Lifetime
- 2004-10-28 PT PT04796697T patent/PT1682131E/pt unknown
- 2004-10-28 AT AT04796697T patent/ATE373477T1/de not_active IP Right Cessation
- 2004-10-28 EP EP04796697A patent/EP1682131B9/en not_active Expired - Lifetime
- 2004-10-28 AU AU2004289213A patent/AU2004289213B2/en not_active Expired
- 2004-10-28 DK DK04796697T patent/DK1682131T3/da active
- 2004-10-28 JP JP2006539565A patent/JP4856548B2/ja not_active Expired - Lifetime
- 2004-10-28 ES ES04796697T patent/ES2291954T3/es not_active Expired - Lifetime
- 2004-10-28 WO PCT/US2004/035900 patent/WO2005046681A1/en not_active Ceased
- 2004-10-28 PL PL04796697T patent/PL1682131T3/pl unknown
- 2004-10-28 RU RU2006119451/14A patent/RU2358731C2/ru active
- 2004-10-28 BR BRPI0415714-1A patent/BRPI0415714A/pt not_active Application Discontinuation
- 2004-10-28 KR KR1020067010939A patent/KR101387988B1/ko not_active Expired - Lifetime
- 2004-10-29 TW TW093132942A patent/TW200517116A/zh unknown
- 2004-11-01 MY MYPI20044512A patent/MY136436A/en unknown
- 2004-11-02 PE PE2004001059A patent/PE20051000A1/es not_active Application Discontinuation
- 2004-11-02 PA PA20048616601A patent/PA8616601A1/es unknown
- 2004-11-02 US US10/979,284 patent/US20050113403A1/en not_active Abandoned
- 2004-11-03 GT GT200400224A patent/GT200400224A/es unknown
- 2004-11-20 SA SA04250375A patent/SA04250375B1/ar unknown
-
2006
- 2006-04-24 IL IL175128A patent/IL175128A0/en unknown
- 2006-05-03 ZA ZA200603533A patent/ZA200603533B/en unknown
- 2006-05-05 CR CR8383A patent/CR8383A/es not_active Application Discontinuation
- 2006-05-19 NO NO20062271A patent/NO20062271L/no not_active Application Discontinuation
- 2006-05-31 CO CO06052238A patent/CO5690605A2/es not_active Application Discontinuation
- 2006-06-02 EC EC2006006600A patent/ECSP066600A/es unknown
-
2011
- 2011-04-01 US US13/078,272 patent/US8507518B2/en not_active Expired - Fee Related
-
2012
- 2012-05-31 IL IL220080A patent/IL220080A0/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060002A1 (es) | Combinaciones antineoplasicas de cci-779 y rituximab | |
| ECSP055788A (es) | Sistema de suministro de fármacos | |
| RU2009101324A (ru) | Композиции и способы лечения воспаления слизистой оболочки | |
| EA201290833A1 (ru) | Применение амисульприда в качестве противорвотного средства | |
| CZ309247B6 (cs) | 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru | |
| EA200501819A1 (ru) | Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке | |
| CO6160236A2 (es) | Inhibidor de quinasa | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| AR095338A1 (es) | Método de tratamiento no tóxico para la abstinencia de drogas | |
| AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
| AR077225A1 (es) | Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza | |
| HRP20240082T1 (hr) | Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| AR065731A1 (es) | Composiciones farmaceuticas que contienen 2-[6-(3-amino-pipenidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-primidin-1-il metil]-4-fluoro-benzonitrilo. uso. metodo de tratamiento, administracion semanal de inhibidores de la dipeptidilpeptidasa. | |
| IL196425A (en) | Dosage unit for oral administration containing ibuprofen and pamotidine | |
| WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
| EA200601901A1 (ru) | Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов и способы с их использованием | |
| NO20065915L (no) | Forbedring av barriereintegritet i HIV-pasienter | |
| TW200509992A (en) | Dosage form containing pantoprazole as active ingredient | |
| AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
| BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t | |
| CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
| PE20051000A1 (es) | 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metil propionico (cci-779)" | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
| NZ595798A (en) | Ectoparasiticidal methods and formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |